KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Enterprise Value (2016 - 2025)

Historic Enterprise Value for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to -$7.1 million.

  • TherapeuticsMD's Enterprise Value fell 4097.48% to -$7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.1 million, marking a year-over-year decrease of 4097.48%. This contributed to the annual value of -$5.1 million for FY2024, which is 1691.7% down from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's Enterprise Value is -$7.1 million, which was down 4097.48% from -$6.1 million recorded in Q2 2025.
  • Over the past 5 years, TherapeuticsMD's Enterprise Value peaked at -$4.3 million during Q4 2023, and registered a low of -$137.6 million during Q1 2021.
  • Moreover, its 5-year median value for Enterprise Value was -$13.7 million (2023), whereas its average is -$36.4 million.
  • As far as peak fluctuations go, TherapeuticsMD's Enterprise Value soared by 9285.58% in 2023, and later crashed by 4097.48% in 2025.
  • Over the past 5 years, TherapeuticsMD's Enterprise Value (Quarter) stood at -$64.9 million in 2021, then increased by 6.69% to -$60.6 million in 2022, then skyrocketed by 92.86% to -$4.3 million in 2023, then decreased by 16.92% to -$5.1 million in 2024, then crashed by 40.64% to -$7.1 million in 2025.
  • Its Enterprise Value stands at -$7.1 million for Q3 2025, versus -$6.1 million for Q2 2025 and -$5.7 million for Q1 2025.